Literature DB >> 20616151

Early autophagic response in a novel knock-in model of Huntington disease.

Mary Y Heng1, Duy K Duong, Roger L Albin, Sara J Tallaksen-Greene, Jesse M Hunter, Mathieu J Lesort, Alex Osmand, Henry L Paulson, Peter J Detloff.   

Abstract

The aggregation of mutant polyglutamine (polyQ) proteins has sparked interest in the role of protein quality-control pathways in Huntington's disease (HD) and related polyQ disorders. Employing a novel knock-in HD mouse model, we provide in vivo evidence of early, sustained alterations of autophagy in response to mutant huntingtin (mhtt). The HdhQ200 knock-in model, derived from the selective breeding of HdhQ150 knock-in mice, manifests an accelerated and more robust phenotype than the parent line. Heterozygous HdhQ200 mice accumulate htt aggregates as cytoplasmic aggregation foci (AF) as early as 9 weeks of age and striatal neuronal intranuclear inclusions (NIIs) by 20 weeks. By 40 weeks, striatal AF are perinuclear and immunoreactive for ubiquitin and the autophagosome marker LC3. Striatal NIIs accumulate earlier in HdhQ200 mice than in HdhQ150 mice. The earlier appearance of aggregate pathology in HdhQ200 mice is paralleled by earlier and more rapidly progressive motor deficits: progressive imbalance and decreased motor coordination by 50 weeks, gait deficits by 60 weeks and gross motor impairment by 80 weeks of age. At 80 weeks, heterozygous HdhQ200 mice exhibit striatal and cortical astrogliosis and a approximately 50% reduction in striatal dopamine receptor binding. Increased LC3-II protein expression, which is noted early and sustained throughout the disease course, is paralleled by increased expression of the autophagy-related protein, p62. Early and sustained expression of autophagy-related proteins in this genetically precise mouse model of HD suggests that the alteration of autophagic flux is an important and early component of the neuronal response to mhtt.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616151      PMCID: PMC2935855          DOI: 10.1093/hmg/ddq285

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  84 in total

Review 1.  Autophagosome formation: core machinery and adaptations.

Authors:  Zhiping Xie; Daniel J Klionsky
Journal:  Nat Cell Biol       Date:  2007-10       Impact factor: 28.824

Review 2.  How to interpret LC3 immunoblotting.

Authors:  Noboru Mizushima; Tamotsu Yoshimori
Journal:  Autophagy       Date:  2007-06-19       Impact factor: 16.016

3.  Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease.

Authors:  Mary Y Heng; Sara J Tallaksen-Greene; Peter J Detloff; Roger L Albin
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

4.  Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.

Authors:  Andreas Weiss; Corinna Klein; Ben Woodman; Kirupa Sathasivam; Miriam Bibel; Etienne Régulier; Gillian P Bates; Paolo Paganetti
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

5.  HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration.

Authors:  Udai Bhan Pandey; Yakup Batlevi; Eric H Baehrecke; J Paul Taylor
Journal:  Autophagy       Date:  2007-09-10       Impact factor: 16.016

6.  Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity.

Authors:  Randy Singh Atwal; Jianrun Xia; Deborah Pinchev; Jillian Taylor; Richard M Epand; Ray Truant
Journal:  Hum Mol Genet       Date:  2007-08-18       Impact factor: 6.150

7.  A comparison of huntington disease and huntington disease-like 2 neuropathology.

Authors:  Dobrila D Rudnicki; Olga Pletnikova; Jean-Paul G Vonsattel; Christopher A Ross; Russell L Margolis
Journal:  J Neuropathol Exp Neurol       Date:  2008-04       Impact factor: 3.685

8.  Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.

Authors:  Andrea Williams; Sovan Sarkar; Paul Cuddon; Evangelia K Ttofi; Shinji Saiki; Farah H Siddiqi; Luca Jahreiss; Angeleen Fleming; Dean Pask; Paul Goldsmith; Cahir J O'Kane; Rodrigo Andres Floto; David C Rubinsztein
Journal:  Nat Chem Biol       Date:  2008-05       Impact factor: 15.040

Review 9.  Huntington's disease: from pathology and genetics to potential therapies.

Authors:  Sara Imarisio; Jenny Carmichael; Viktor Korolchuk; Chien-Wen Chen; Shinji Saiki; Claudia Rose; Gauri Krishna; Janet E Davies; Evangelia Ttofi; Benjamin R Underwood; David C Rubinsztein
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

Review 10.  The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.

Authors:  Janet E Davies; Sovan Sarkar; David C Rubinsztein
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

View more
  51 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

3.  Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study.

Authors:  Mari Tada; Elizabeth A Coon; Alexander P Osmand; Patricia A Kirby; Wayne Martin; Marguerite Wieler; Atsushi Shiga; Hiroe Shirasaki; Masayoshi Tada; Takao Makifuchi; Mitsunori Yamada; Akiyoshi Kakita; Masatoyo Nishizawa; Hitoshi Takahashi; Henry L Paulson
Journal:  Acta Neuropathol       Date:  2012-06-27       Impact factor: 17.088

Review 4.  Mini-review: Retarding aging in murine genetic models of neurodegeneration.

Authors:  Roger L Albin; Richard A Miller
Journal:  Neurobiol Dis       Date:  2015-10-21       Impact factor: 5.996

5.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

Review 6.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

7.  Allelic series of Huntington's disease knock-in mice reveals expression discorrelates.

Authors:  Ashish Kumar; Jennifer Zhang; Sara Tallaksen-Greene; Michael R Crowley; David K Crossman; A Jennifer Morton; Thomas Van Groen; Inga Kadish; Roger L Albin; Mathieu Lesort; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2016-02-14       Impact factor: 6.150

8.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

Review 9.  A role for autophagy in Huntington's disease.

Authors:  Katherine R Croce; Ai Yamamoto
Journal:  Neurobiol Dis       Date:  2018-08-24       Impact factor: 5.996

10.  Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model.

Authors:  Mary Y Heng; Shu-Ting Lin; Laure Verret; Yong Huang; Sherry Kamiya; Quasar S Padiath; Ying Tong; Jorge J Palop; Eric J Huang; Louis J Ptáček; Ying-Hui Fu
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.